

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10/540,577
Confirmation Number	6428
Filing Date	December 16, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	1614
Examiner Name	Savitha M RAO
Attorney Docket Number	Q86357

## **U.S. PATENTS**

Examiner Initials*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	6960577	B2	2005-11-01	Tollefson	
	2.	5780051	A	1998-07-14	Eswara et al.	
	3.	6159963	A	2000-12-12	Beasley et al.	
	4.	6399608	B1	2002-06-04	Dawson	
	5.	5589512	A	1996-12-31	Norden	
	6.	6395727	B1	2002-05-28	Guadagno et al.	
	7.	5500343	A	1996-03-19	Blum et al.	
	8.	5591884	A	1997-01-07	DeNinno et al	
	9.	4310524	A	1982-01-12	Wiech et al.	
	10.	6322503	B1	2001-11-27	Sparhawk, Jr.	
	11.	6121259	A	2000-09-19	Yelle	
	12.	6352984	B1	2002-03-05	Yette	
	13.	6348455	B1	2002-02-19	Yelle	
	14.	6582737	B2	2003-06-24	Hirsh et al.	
	15.	6174882	B2	2001-01-16	Yelle	
	16.	6066643	A	2000-05-23	Perry	

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initials*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	17.	20020123490	A1	2002-09-05	Howard	
	18.	20030049308	A1	2003-03-13	Theobald	
	19.	20020035145	A1	2002-03-21	Tsai et al.	
	20.	20020040041	A1	2002-04-04	Taylor	
	21.	20020016325	A1	2002-02-07	Taylor	
	22.	20010048943	A1	2001-12-06	Faour et al.	
	23.	20020051807	A1	2001-12-06	Faour et al.	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	24.	0966967	EP	A2	1999-12-29	Tollefson		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10/540,577
Confirmation Number	6428
Filing Date	December 16, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	1614
Examiner Name	Savitha M RAO
Attorney Docket Number	Q86357

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	25.	1238676	EP	A1	2002-09-11	Ralph - Pfizer		
	26.	01/80837	WO	A2	2001-11-01	Theobald et al.		
	27.	95/00154	WO	A1	1995-01-05	Hemisphere Limit		
	28.	99/058130	WO	A1	1999-11-18	Pharmacia & Upio		
	29.	01/51041	WO	A1	2001-07-19	Laboratorios Ph		
	30.	01/51040	WO	A1	2001-07-19	Laboratorios Ph		

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	31.	Adli, M. et al. "Algorithms for optimizing the treatment of depression: making the right decision at the right time", Pharmacopsychiatry, Nov. 2003, Supp 3:S222-9.	
	32.	American Academy of Pediatrics, Committee on Nutrition, "The Use and Misuse of Fruit Juice in Pediatrics", Pediatrics (2001) vol. 107, no. 5, pp. 1210-1213.	
	33.	Azhar, M. Z., "Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan — implications for management by family doctors", Med. J. Malaysia 2000 55(4)402-8.	
	34.	Barbee, J. G., et al. "Lamotrigine as an augmentation agent in treatment-resistant depression," J. Clin Psychiatry, 63:8 August 2002, p 737-741.	
	35.	Barlow, D. H., "Anxiety and its disorders (learned alarms) pages 220-225, Guilford Press, 1988.	
	36.	Battaglia, J., et al. "Structured assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department", International Clinical Psychopharmacology 1999, 14: 361-372.	
	37.	Beasley, C. M., et al., "Olanzapine versus placebo and Haloperidol: Acute phase results of the North American double-blind olanzapine trial", Neuropsychopharmacology 14: 111-123, 1996.	
	38.	Berman et al., "Antidepressant Effects of Ketamine in Depressed Patients," Biological Psychiatry (2000) Vol. 47, pp. 351-354.	
	39.	Blum, A., "Patients at risk of developing severe side effects from depot fluphenazine treatment", Am J Psychiatry 137:2 1980, 254-255.	
	40.	Brody A., et al., "Regional brain metabolic changes in patients with major depression treated with either paroxetine or Interpersonal therapy", Arch Gen Psychiatry 2001; 58:631-640.	
	41.	Casey et al., "An integrated cognitive model of panic disorder: The role of positive and negative cognitions", Clinical Psychology Review (2004) vol. 24 pp. 529-555.	
	42.	Chemical Abstracts Registry entry number 129722-12-9 (aripiprazole), entered into STN on October 5, 1990.	
	43.	Cremers, T.I., et al., "Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol. Psychiatry 2001, Jul 1; 50(1):13-21.	
	44.	Current Patents 15 Nov 2002 week 0246 at <a href="http://scientific.thompson.com/media/cdjournal/gazettenews/202/CPG_News_0246.pfd">http://scientific.thompson.com/media/cdjournal/gazettenews/202/CPG_News_0246.pfd</a> .	
	45.	DE ADSON, M.D., et al., "An Open Trial of Quetiapine for Anxiety in Patients Receiving an SSRI"; Society of Biological Psychiatry Annual Meeting; May 16-18, 2002: Philadelphia, Pennsylvania.	
	46.	DeRubeis, R. J. et al., "Cognitive therapy vs Medications in the treatment of moderate to severe depression", Arch Gen Psychiatry 2005; 62:409-416.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/540,577
Confirmation Number	6428
Filing Date	December 16, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	1614
Examiner Name	Savitha M RAO
Attorney Docket Number	Q86357

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	47.	Drake, R.E., et al, "Suicide attempts associated with akathisia" Am J Psychiatry 142:4, April 1985.	
	48.	Evins, et al., "Bupropion and smoking cessation", (Am. J. Psychiatry 156:5, May 1999, pages 798-799.)	
	49.	Ferris, R.M., et al, "Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic $\beta$ -adrenergic, serotonergic (5-HT <sub>2</sub> ), $\alpha_2$ -adrenergic, imipramine and dopaminergic receptors in brain", Neuropharmacology 22 No II, 1257-1267, 1983.	
	50.	George, T., et al., "A Placebo-Controlled Trial of Bupropion for Smoking Cessation in Schizophrenia" (2002) Biological Psychiatry, vol. 52, pp. 53-61.	
	51.	Goldapple K., et al, "Modulation of cortical-limbic pathways in major depression", Arch. Gen Psychiatry, Vol. 61, Jan 2004, pages 34-41.	
	52.	Hirose, S., et al., "An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy", J. Clin Psychiatry Vol 63, (8) August 2002, pages 733-736.	
	53.	Hirsch, S.R., et al., "The concept and efficacy of the treatment of parasuicide", Br J. Clin Pharmac 1983, 15, 189S-194S.	
	54.	Interview with Hussein Katz director of neuropharmacological drug products at the FDA - Tribune Review March 23 2004 (Antidepressants...)	
	55.	Interview with Robert Temple director of FDA's Office of Medical Policy - Pittsburgh Post-Gazette December 14 2006 (FDA may expand alert...)	
	56.	JAMBUR ANANTH, "Treatment-Resistant Depression"; Psychother. Psychosom.; 1998; Pages 61-70; 67; S. Karger AG, Basel, Switzerland	
	57.	Kelleher et al., "Advances in Atypical Antipsychotics for the Treatment of Schizophrenia" CNS Drugs (2002) Vol. 16, No. 4, pp. 249-261.	
	58.	Kramer, M.S., et al, "The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia", Arch Gen Psychiatry 1997; 54:567-572.	
	59.	Kuoppamaki, M. et al. "Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs". Neuropsychopharmacology, 13:139-150, 1995.	
	60.	Landen M. et al A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J. Clin Psychiatry 1998; 59:664-668.	
	61.	Lipinski, J. F., et al., "Fluoxetine-induced akathisia: Clinical and theoretical implications", J. Clin. Psychiatry 50:9 1989 339-342.)	
	62.	Montgomery, S.A. et al. "The prevention of Recurrent Suicidal Acts", Br. J. Clin. Pharmac 1983, 15, 183S-188S.	
	63.	Nair, NPV et al., "Neurochemical and receptor theories of depression", Psychiat. J. Univ Ottawa, vol 14(2) 1989 pp 328- 341.	
	64.	Ost, et al., "Probability ratings in claustrophobic patients and normal controls" Behavior Research and Therapy (2000) Vol. 38 pp. 1107-1116.	
	65.	Paton, C., "Generic clozapine: outcomes after switching formulations", British Journal of Psychiatry 2006, vol. 189, p. 184-185.	
	66.	Perez, V. et al, "A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors", Arch. Gen. Psychiatry. 1999; 56(4):375-379.	
	67.	Pivac et al., "Collegium Internationale Neuro-Psychopharmacologicum", Psychiatria Danubina (2002) Vol. 14, no. 3-4, pp. 231-242.	
	68.	Poyurovsky M., et al., "Mirtazapine for the neuroleptic-induced akathisia", Am J Psychiatry 158:5 (2001) p. 819.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/540,577
Confirmation Number	6428
Filing Date	December 16, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	1614
Examiner Name	Savitha M RAO
Attorney Docket Number	Q86357

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	69.	Reeves, H. et al., "Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled study", J. Clin Psychiatry 69:8 (August 2008).	
	70.	Robertson, et al., "Major Tranquilizers Used as Antidepressants", Journal of Affective Disorders (1982) Vol. 4, pp. 173-193.	
	71.	Roth B.L. et al, "Chronic mianserine treatment decreases 5-HT <sub>2</sub> receptor binding without altering 5-HT <sub>2</sub> receptor mRNA levels", European Journal of Pharmacology - Molecular Pharmacology Section, 207 (1991) 169-172.	
	72.	Roth et al., "D <sub>4</sub> Dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs," Psychopharmacology (1995) vol. 120, pp. 365-368.	
	73.	Roy, A. et al., "Marked Reduction in Indexes of Dopamine Metabolism Among Patients With Depression Who Attempt Suicide", Arc Gen Psychiatry 49, 1992, 447-450.	
	74.	Schmidt, et al., "Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile" European Journal of Pharmacology (2001), vol. 425, pp. 197-201.	
	75.	Sharp, D.M. et al, "Global measures of outcome in controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care", Br. J. Gen. Pract. 1997 47(416) 150-155.	
	76.	Shaw, E.D. et al, "A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study", J. Clin. Psychopharmacol. Vol 6(3) 1986 196-197.	
	77.	Shear, M.K., et al., "Suicide associated with akathisia and depot fluphenazine treatment", Journal of Clinical Psychopharmacology, Vol. 3(4) 1983 235-236.	
	78.	Simon, N.M., et al., "Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder" Journal of Affective Disorders 69, (2002) 201-208.	
	79.	Smith, W.T. et al., "Short term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study". Am J Psychiatry 155:10, 1998, 1339-45.	
	80.	Souery, D. et al.; "Treatment resistant depression: methodological-overview and operational criteria"; European Neuropsychopharmacology; 1999; Pages 83-91; 9; Elsevier Science B.V./ECNP; Amsterdam, The Netherlands.	
	81.	Steiner M., "The neurochemistry of mood", Psychiat J. Univ Ottava, vol 14(2) 1989 pp342-343.	
	82.	Stoner, S.C. et al. "A program to convert patients from Trade-name to generic clozapine" Pharmacotherapy 2003; 23(6):806-810.	
	83.	Tang et al., PNU-96415E, "A Potential Antipsychotic Agent with Clozapine-Like Pharmacological Properties" The Journal of Pharmacology and Experimental Therapeutics (1997) vol. 281, pp. 440-447.	
	84.	Thase, MICHAEL E., M.D.; "What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression?"; The Journal of Clinical Psychiatry: February, 2002; Pages 95-103; 63:2; Physicians Postgraduate Press, Inc. Memphis, Tennessee.	
	85.	The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, ed. by Beers and Berkow, pp. 1531-1538 and 1569-1570.	
	86.	Tollefson G.D., et al. (1998b) "A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia", Biol. Psychiatry, 1998; 43:803-810.	
	87.	Tollefson, G.D., et al. (1998a) "Depressive signs and symptoms in Schizophrenia. A prospective blinded trial of olanzapine and haloperidol", Arch Gen Psychiatry 98; 55:250- 258.	
	88.	Toth M., et al, "Antagoist-mediated downregulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription. Molecular pharmacology 45:1095-110, 1994.	
	89.	Trivedi, M. H., et al., "Clinical Results for Patients with Major Depressive Disorder in the Texas Medication Algorithm Project", Arch. Gen. Psychiatry, Vol. 61, July 2004 p. 669-680.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10/540,577
Confirmation Number	6428
Filing Date	December 16, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	1614
Examiner Name	Savitha M RAO
Attorney Docket Number	Q86357

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	90.	Tsai, G. E. "A new class of antipsychotic drugs enhancing neurotransmission by NMDA receptors", Psychiatric Times December 2008, p 16-18.	
	91.	Uhlenhuth et al., "The revised Anxious Thoughts and Tendencies (AT&T) scale: a general measure of anxiety-prone cognitive style" Journal of Affective Disorders (1999), vol. 52, pp. 51-58.	
	92.	Van Putten, T. "The many faces of akathisia" Comprehensive Psychiatry, Vol. 16 (1) 1975 43- 47.	
	93.	Van Putten, T. et al. "Behavioral toxicity of antipsychotic drugs", J. Clin. Psychiatry 48 [9, Suppl]:13-19, 1987.	
	94.	Viner, M.W., et al. "Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation", Journal of Clinical Psychopharmacology 23:1 (2003) p. 104-106.	
	95.	WHfoods, "Is Fruit Juice as good as whole fruit" published online at <a href="http://www.whfoods.com/genpage.php?tname=george&amp;dbid=74">http://www.whfoods.com/genpage.php?tname=george&amp;dbid=74</a> 8/25/2008.	
	96.	Zubenko, G. et al, "Antidepressant-related akathisia" J. Clin. Psychopharmacol Vol 7(4) 1987 254-257.	

## **EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.